Kazia Annual Report 2022

56 FINANCIAL REPORT NOTES TO THE FINANCIAL STATEMENTS CONTINUED 30 June 2022 Note 6. Other income Consolidated 2022 2021 $ $ Payroll tax rebate - 2,192 Subsidies and grants 10,000 - Bad debt recovery 14,956 - Other income 24,956 2,192 Note 7. Expenses Consolidated 2022 2021 $ $ Loss before income tax includes the following specific expenses: Research and development EVT-801 program costs 2,519,673 1,073,253 Cantrixil program costs 11,614 429,441 Paxalisib program costs 13,713,454 11,403,531 Employee benefits expense - salaries & wages and staff benefits 1,664,572 336,114 - superannuation 25,198 25,720 - share based payment 364,700 7,998 Total research & development (excluding amortisation) 18,299,211 13,276,057 Amortisation Paxalisib licensing agreement 1,084,351 1,084,344 Evotech licensing agreement 868,590 180,965 Total amortisation 1,952,941 1,265,309 Total research and development 20,252,152 14,541,366 Net foreign exchange loss Net foreign exchange loss - 430,273 Leases Expense relating to short term leases 73,138 92,552 Employee benefits expense G&A - salaries & wages and staff benefits 1,674,344 1,011,338 - superannuation 129,241 112,290 - share based payment 1,309,880 551,530 Total employee benefits expense G&A 3,113,465 1,675,158 Other expenses Chinese With-Holding Tax incurred on license transaction - 931,099 Chinese Value Added Tax incurred on license transaction - 537,578 - 1,468,677

RkJQdWJsaXNoZXIy MjE2NDg3